José Dinis

4.1k total citations
29 papers, 493 citations indexed

About

José Dinis is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Otorhinolaryngology. According to data from OpenAlex, José Dinis has authored 29 papers receiving a total of 493 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 12 papers in Otorhinolaryngology. Recurrent topics in José Dinis's work include Head and Neck Cancer Studies (11 papers), Lung Cancer Treatments and Mutations (11 papers) and Cancer Immunotherapy and Biomarkers (8 papers). José Dinis is often cited by papers focused on Head and Neck Cancer Studies (11 papers), Lung Cancer Treatments and Mutations (11 papers) and Cancer Immunotherapy and Biomarkers (8 papers). José Dinis collaborates with scholars based in Portugal, United States and Italy. José Dinis's co-authors include Lisa Licitra, Ezra E.W. Cohen, Arlene Taylor, Daniel T. T. Chua, Alexandra D. Carides, Judith A. Boice, Fausto Roila, James S. Hardwick, Jørn Herrstedt and Steven M. Grunberg and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

José Dinis

25 papers receiving 485 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
José Dinis Portugal 11 226 219 137 127 83 29 493
Hiroshi Nakade Japan 13 233 1.0× 245 1.1× 18 0.1× 207 1.6× 99 1.2× 31 456
Takahito Taniura Japan 12 163 0.7× 246 1.1× 13 0.1× 160 1.3× 83 1.0× 25 403
Shigeru Lee Japan 13 227 1.0× 172 0.8× 10 0.1× 143 1.1× 69 0.8× 79 443
Ziv Gamliel United States 13 203 0.9× 126 0.6× 37 0.3× 404 3.2× 73 0.9× 26 575
Akiyuki Wakita Japan 14 310 1.4× 159 0.7× 14 0.1× 223 1.8× 68 0.8× 58 577
Yu Nakaji Japan 11 213 0.9× 230 1.1× 10 0.1× 214 1.7× 82 1.0× 28 501
Tadahisa Fukui Japan 7 50 0.2× 135 0.6× 16 0.1× 47 0.4× 58 0.7× 19 335
Qi‐Xin Shang China 13 280 1.2× 129 0.6× 12 0.1× 220 1.7× 85 1.0× 53 443
D.C. Fermont United Kingdom 8 114 0.5× 112 0.5× 114 0.8× 113 0.9× 12 0.1× 10 356
Hakan Karagöl Türkiye 12 133 0.6× 178 0.8× 53 0.4× 157 1.2× 6 0.1× 35 489

Countries citing papers authored by José Dinis

Since Specialization
Citations

This map shows the geographic impact of José Dinis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by José Dinis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites José Dinis more than expected).

Fields of papers citing papers by José Dinis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by José Dinis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by José Dinis. The network helps show where José Dinis may publish in the future.

Co-authorship network of co-authors of José Dinis

This figure shows the co-authorship network connecting the top 25 collaborators of José Dinis. A scholar is included among the top collaborators of José Dinis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with José Dinis. José Dinis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Colevas, A. Dimitrios, Bruno Fang, Diogo Alpuim Costa, et al.. (2024). Safety and Tolerability of Magrolimab Combination Therapy in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (RM-HNSCC). International Journal of Radiation Oncology*Biology*Physics. 118(5). e85–e86.
3.
Harrington, Kevin J., Ezra E.W. Cohen, Denis Soulières, et al.. (2023). Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence. Oral Oncology. 147. 106587–106587. 7 indexed citations
4.
Vieira, Cláudia, et al.. (2023). A New Era in Salivary Gland Carcinoma Treatment: A Case Report. Cureus. 15(8). e42983–e42983.
5.
Colevas, A. Dimitrios, Venessa Chin, John Park, et al.. (2023). 675 Safety and tolerability of magrolimab combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma (RM-HNSCC). SHILAP Revista de lepidopterología. A765–A766.
6.
Dinis, José, et al.. (2020). A 10-year review of primary major salivary gland cancers. ecancermedicalscience. 14. 1055–1055. 8 indexed citations
7.
Harrington, Kevin J., Denis Soulières, Christophe Le Tourneau, et al.. (2020). Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040. JNCI Journal of the National Cancer Institute. 113(2). 171–181. 24 indexed citations
8.
Guerreiro, I., et al.. (2019). Management of Locally Advanced Esthesioneuroblastoma in a Pregnant Woman. SHILAP Revista de lepidopterología. 2019. 1–5. 1 indexed citations
9.
Soulières, Denis, Ezra E.W. Cohen, Christophe Le Tourneau, et al.. (2018). Abstract CT115: Updated survival results of the KEYNOTE-040 study of pembrolizumab vs standard-of-care chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma. Cancer Research. 78(13_Supplement). CT115–CT115. 23 indexed citations
10.
Cohen, Ezra E.W., Kevin J. Harrington, Christophe Le Tourneau, et al.. (2017). Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial. Annals of Oncology. 28. v628–v628. 60 indexed citations
11.
Saloura, Vassiliki, Ezra E.W. Cohen, Lisa Licitra, et al.. (2014). An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck. Cancer Chemotherapy and Pharmacology. 73(6). 1227–1239. 66 indexed citations
12.
13.
Grunberg, Steven M., Daniel T. T. Chua, José Dinis, et al.. (2011). Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol—EASE. Journal of Clinical Oncology. 29(11). 1495–1501. 158 indexed citations
14.
Veiga, Isabel, Franclim R. Ribeiro, Joana Vieira, et al.. (2010). Chromosome copy number changes carry prognostic information independent of KIT/PDGFRA point mutations in gastrointestinal stromal tumors. BMC Medicine. 8(1). 26–26. 13 indexed citations
15.
Barroso, Sérgio, José Dinis, João F. Lacerda, et al.. (2009). Biossimilares em oncologia.. SHILAP Revista de lepidopterología. 1 indexed citations
16.
Veiga, Isabel, Joana Vieira, Carla Pinto, et al.. (2009). Hereditary gastrointestinal stromal tumors sharing the KIT Exon 17 germline mutation p.Asp820Tyr develop through different cytogenetic progression pathways. Genes Chromosomes and Cancer. 49(2). 91–98. 15 indexed citations
17.
Moreira, António Carrizo, et al.. (2008). Perfil da doença oncológica em Portugal racional, objectivos e metodologia - estudo perfil.. SHILAP Revista de lepidopterología. 1 indexed citations
18.
Barroso, Sérgio Girão, José Dinis, Helena Gervásio, et al.. (2008). [Guidelines for prevention of febrile neutropenia].. PubMed. 21(1). 7–19. 1 indexed citations
19.
Santos, Mònica, Maria do Carmo Costa, Maria Edite Rio, et al.. (2004). Genotypes at the APOE and SCA2 loci do not predict the course of multiple sclerosis in patients of Portuguese origin. Multiple Sclerosis Journal. 10(2). 153–157. 23 indexed citations
20.
Santos, Mònica, Jorge Pinto‐Basto, M. E. Rio, et al.. (2003). A whole genome screen for association with multiple sclerosis in Portuguese patients. Journal of Neuroimmunology. 143(1-2). 112–115. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hiroshi Nakade Breakdown of academic impact, for papers by Takahito Taniura Breakdown of academic impact, for papers by Shigeru Lee Breakdown of academic impact, for papers by Ziv Gamliel Breakdown of academic impact, for papers by Akiyuki Wakita Breakdown of academic impact, for papers by Yu Nakaji Breakdown of academic impact, for papers by Tadahisa Fukui Breakdown of academic impact, for papers by Qi‐Xin Shang Breakdown of academic impact, for papers by D.C. Fermont Breakdown of academic impact, for papers by Hakan Karagöl
Rankless by CCL
2026